6-Bromo-1a(2),3a(2)-dihydrospiro[2H-1-benzopyran-2,2a(2)-[2H]inden]-4(3H)-one | 1212021-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-Bromo-1a(2),3a(2)-dihydrospiro[2H-1-benzopyran-2,2a(2)-[2H]inden]-4(3H)-one
• 英文别名: 6'-bromospiro[1,3-dihydroindene-2,2'-3H-chromene]-4'-one
• CAS: 1212021-43-6
• 化学式: C₁₇H₁₃BrO₂
• 分子量: 329.2
• InChiKey: QNNQDZNWVHWNNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Inhibitors Of Beta-Secretase
  申请人：Dillard Lawrence W.

  公开号：US20110218192A1

  公开（公告）日：2011-09-08

  The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.

  本发明涉及以下结构式所表示的化合物或其药学上可接受的盐。还描述了包含由结构式（I）所表示的化合物的药物组合物和使用这些化合物抑制需要此类治疗的受体中的BACE活性的方法。
• INHIBITORS OF BETA-SECRETASE
  申请人：Dillard Lawrence W.

  公开号：US20130317014A1

  公开（公告）日：2013-11-28

  The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.

  本发明涉及以下结构式所代表的化合物：或其药学上可接受的盐。还描述了包括结构式（I）所代表的化合物的药物组合物以及使用这些化合物抑制需要此类治疗的受体中的BACE活性的方法。
• US8450308B2
  申请人：——

  公开号：US8450308B2

  公开（公告）日：2013-05-28
• US8921359B2
  申请人：——

  公开号：US8921359B2

  公开（公告）日：2014-12-30
• [EN] INHIBITORS OF BETA-SECRETASE<br/>[FR] INHIBITEURS DE LA BÊTA-SÉCRÉTASE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2010021680A2

  公开（公告）日：2010-02-25

  The present invention is directed to a compound represented by the following structural formula:or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Strucutral Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.